easeLabs

Ease Labs offers cannabis products with a focus on quality, safety, and innovation.

Ease Labs produces cannabis extracts for therapeutic treatment applications.

Natural treatments are gaining prominence, as herbal medicine and phytopharmaceuticals—derived from medicinal plants—have scientific backing.

The page outlines the main cannabis extraction methods used by the industry.

Quality of life and well-being are key focuses in modern health discussions, with medicine advancing toward more natural solutions.

Ease Labs is updating its packaging to comply with Anvisa’s RDC No. 1015/2026, detailing changes and continuities for Cannabis Extract and Cannabidiol products.

Ease Labs develops innovative natural solutions specializing in cannabis and botanical ingredients, adhering to Anvisa’s quality and safety standards.

Ease Labs partners with pharmacies and networks to supply cannabis products with guaranteed pharmaceutical quality and scientific excellence.

Ease Labs is negotiating with European partners to export medical cannabis products, including active pharmaceutical ingredients and finished goods. The Brazilian company targets international expansion in the medical cannabis market through these discussions. Talks focus on establishing supply chains and commercial agreements for its cannabis-derived offerings.

Oct 2026SechatNews article

Ease Labs is investing **R$100 million** to expand its operations and enter the **cannabis export market**. The Brazilian company specializes in cannabis-derived products and aims to strengthen its global presence through this funding. The move follows rising demand for medical and recreational cannabis in international markets.

Oct 2026valorinternationalNews article

Avicanna and Ease Labs Pharma receive Brazil’s first commercialization approval for a THC-containing pharmaceutical product from ANVISA. The approval marks a milestone for domestically produced cannabis-based medicines in the country.

Jan 2024AvicannaNews article

Ease Labs Pharma secures approval from Brazil’s Health Regulatory Agency to commercialize its **Cannabis sativa full-spectrum extract**, containing **750mg CBD (25mg/mL)** and up to **0.2% THC**, alongside other cannabinoids. The product, developed at the company’s **GMP-certified facility in Belo Horizonte**, marks Brazil’s first locally manufactured full-spectrum cannabis extract. It will now be available for distribution within the country.

Jan 2024PR NewswireNews article